← Research LibraryThe BriefFY2025 20-F · headline figures audited against SEC data
ICON restated its 2023 and 2024 accounts after an investigation into clinical trial revenue, and in 2025 operating income fell 57.1% to $442.8 million on $465.3 million of Data Solutions impairments while revenue was flat at $8.25B.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +0.8% to $8.25B; +0.1% in constant currencyWatch
- Profitability — Operating margin 5.4%, down 724 bps; net income -69.0%Watch
- Balance sheet — $500M notes due July 2026, $750M due May 2027Note
- Accounting quality — 2023 and 2024 restated; material weaknesses in internal controlWatch
- Capital allocation — Buybacks $0.75B, up 50.0%; no dividendNote
- Backlog — Unsatisfied performance obligations $14.9B, from $15.9BWatch
Business
ICON is a contract research organization founded in Dublin in 1990. It runs clinical trials and related development services for pharmaceutical, biotechnology, medical device and public health customers, with about 40,100 employees in 55 countries, and reports in U.S. dollars as one reportable segment.
Latest filings
- 6-K · Company announcement (foreign filer)2026-10-08
- 6-K · Company announcement (foreign filer)2026-09-09
- 6-K · Company announcement (foreign filer)2026-08-20
- 6-K · Company announcement (foreign filer)2026-08-18
- 6-K · Company announcement (foreign filer)2026-08-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ICON PLC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.